Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-116 manufacturers

Filters

None products found

pp-116

Solution for injection/infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
China
Comments
Indication: Advanced or metastatic solid tumors; expanded investigation in high‑risk non‑muscle‑invasive bladder cancer (NMIBC), including BCG‑unresponsive patients where immunotherapy options are limited Clinical stage: Phase I / Phase I–II clinical development globally (multiple open‑label studies in advanced solid tumors and NMIBC) Modality: Biologic (bi‑functional fusion protein / engineered antibody) Mechanism / Target: Binds PD‑L1 to block the PD‑1/PD‑L1 immunosuppressive pathway and delivers attenuated IL‑15/IL‑15Rα sushi domain to the tumor microenvironment to activate NK cells and CD8+ T cells, combining immune checkpoint blockade with cytokine‑driven immune activation Route / form: Intravenous infusion (injection) Differentiation: Designed as a dual‑mechanism cancer immunotherapy combining immune checkpoint blockade with local cytokine stimulation to overcome resistance seen with PD‑(L)1 inhibitors alone; engineered IL‑15 portion aims to increase tolerability and tumor‑focused activation while minimizing systemic toxicity
Manufacturer #39090

Clinical-stage pharmaceutical company focused on oncology, neuroscience, and autoimmune diseases. Develops innovative and generic medicines with growing global ambitions. Strategy includes partnerships and selective international expansion.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.